Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 2
1949 1
1951 1
1952 1
1953 6
1954 5
1955 5
1956 5
1957 10
1958 8
1959 2
1961 3
1963 1
1964 4
1965 75
1966 135
1967 174
1968 173
1969 184
1970 252
1971 328
1972 383
1973 390
1974 436
1975 399
1976 432
1977 369
1978 372
1979 311
1980 307
1981 320
1982 303
1983 255
1984 326
1985 278
1986 267
1987 255
1988 245
1989 233
1990 224
1991 259
1992 273
1993 234
1994 228
1995 299
1996 279
1997 278
1998 347
1999 331
2000 367
2001 351
2002 340
2003 381
2004 352
2005 333
2006 437
2007 439
2008 419
2009 423
2010 486
2011 586
2012 720
2013 899
2014 962
2015 895
2016 834
2017 903
2018 862
2019 838
2020 873
2021 866
2022 888
2023 725
2024 818
2025 907
2026 497

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25,370 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma.
Shi GM, Huang XY, Liang F, Liang X, Dong R, Ye QH, Gao Q, Ji Y, Yu ZP, Zhai WL, Lu JC, Li XW, Liu FB, Wang K, Yang W, Zhang JL, Hu ZQ, Qiu SJ, Wang XY, Yang XR, Sun HC, Shi YH, Ding ZB, Liu WR, Huang XW, Huang C, Shen YH, Sun J, He YF, Peng YF, Xu Y, Zou JJ, Zhou J, Fan J; ZSAB Study Group. Shi GM, et al. N Engl J Med. 2026 Mar 5;394(10):983-995. doi: 10.1056/NEJMoa2513918. N Engl J Med. 2026. PMID: 41780001 Clinical Trial.
Sickle cell disease.
Colombatti R, Jastaniah W, Makani J, Andemariam B. Colombatti R, et al. Lancet. 2026 Mar 14;407(10533):1095-1111. doi: 10.1016/S0140-6736(25)02278-0. Lancet. 2026. PMID: 41831848 Review.
Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study.
Mesa R, Gill H, Zhang L, Jin J, Kirito K, Komatsu N, Qin A, Xiao Z, Tashi T, Shimoda K, Ohishi K, Chen S, Zuo X, Shirane S, Hu Y, Zhang S, Wang Y, Takenaka K, Ichii M, Xu N, Shih LY, Lim KH, Lee SE, Bae SH, Teo WZY, Maze D, Oh ST, Bose P, Sato T, Zagrijtschuk O, Lin S, Shih WJ, Mascarenhas J, Masarova L; SURPASS-ET Study Group. Mesa R, et al. Lancet Haematol. 2025 Nov;12(11):e862-e875. doi: 10.1016/S2352-3026(25)00264-9. Lancet Haematol. 2025. PMID: 41193116 Clinical Trial.
Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.
Montesinos P, Rodríguez-Veiga R, Bergua JM, Algarra Algarra JL, Botella C, Rodríguez-Arbolí E, Bernal T, Tormo M, Calbacho M, Salamero O, Serrano J, Noriega V, López-López JA, Vives S, López-Lorenzo JL, Colorado M, Vidriales MB, García Boyero R, Olave MT, Herrera Puente P, Arce O, Barrios M, Jose Sayas M, Polo M, Gómez-Roncero MI, Barragán E, Ayala R, Chillón C, Calasanz MJ, Paiva B, Boluda B, Casas-Avilés I, Lloret-Madrid P, Sánchez MJ, Rodríguez-Medina C, Cuevas L, Raposo-Puglia JÁ, Mateos MC, Olivares M, Martínez-Chamorro C, Alonso N, Suárez S, Sánchez-Vadillo I, Solé Rodríguez M, González BJ, Martínez-Francés A, Cuello R, Fernández A, Martínez-Cuadrón D, Labrador J; PETHEMA group; PETHEMA Group. Montesinos P, et al. J Clin Oncol. 2026 Jan;44(1):42-53. doi: 10.1200/JCO-25-01841. Epub 2025 Oct 13. J Clin Oncol. 2026. PMID: 41082703 Free PMC article. Clinical Trial.
Reirradiation in recurrent glioblastoma.
Kazda T, Hnidakova L, Minniti G. Kazda T, et al. Curr Opin Oncol. 2025 Nov 1;37(6):580-588. doi: 10.1097/CCO.0000000000001192. Epub 2025 Sep 3. Curr Opin Oncol. 2025. PMID: 41057143 Review.
FLT3-ITD measurable residual disease from the QuANTUM-First trial.
Levis MJ, Erba HP, Montesinos P, Kim HJ, Vrhovac R, Patkowska E, Žák P, Wang PN, Connolly Rohrbach JE, Chang KCN, Liu L, Mostafa Kamel Y, Imadalou K, Lesegretain A, Cortes J, Sekeres MA, Dombret H, Amadori S, Wang J, Schlenk RF, Perl AE. Levis MJ, et al. Blood Adv. 2026 Feb 10;10(3):917-928. doi: 10.1182/bloodadvances.2025016444. Blood Adv. 2026. PMID: 41052406 Free PMC article. Clinical Trial.
Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma.
Arance A, Berciano-Guerrero MA, Guo J, Carlino MS, Ascierto PA, Burotto M, Mortier L, Queirolo P, Chiarion-Sileni V, Schachter J, Zhang X, Martin-Liberal J, Del Vecchio M, Okpara CE, Dutcus C, Zhang J, Diede SJ, Neff T, Long GV. Arance A, et al. Ann Oncol. 2025 Dec;36(12):1535-1546. doi: 10.1016/j.annonc.2025.08.008. Epub 2025 Aug 28. Ann Oncol. 2025. PMID: 40885529 Free article. Clinical Trial.
Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775.
Makker V, Colombo N, Casado A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Yonemori K, Kim YM, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Kristeleit R, Nishio S, Suzuki S, Guerra Alía EM, Sanli UA, Selle F, Shikama A, Martínez Rodríguez JL, Arik Z, Arican A, Sebastianelli A, Yu Z, McKenzie J, Kruger S, Meng R, Okpara CE, Lorusso D. Makker V, et al. J Immunother Cancer. 2026 Feb 19;14(2):e013713. doi: 10.1136/jitc-2025-013713. J Immunother Cancer. 2026. PMID: 41714113 Free PMC article. Clinical Trial.
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study.
Shi G, Huang X, Li X, Liang F, Gao Q, Zhang D, Lu J, Ji Y, Hu Z, Chen Y, Qiu S, Yi Y, Zhu X, Sun H, Shi Y, Peng M, Wang X, Huang C, Ding Z, He Y, Shen Y, Xu Y, Xiao Y, Hu J, Zhou J, Fan J. Shi G, et al. Lancet Oncol. 2025 Oct;26(10):1334-1345. doi: 10.1016/S1470-2045(25)00376-6. Epub 2025 Aug 29. Lancet Oncol. 2025. PMID: 40889502 Clinical Trial.
25,370 results
You have reached the last available page of results. Please see the User Guide for more information.